All News

A new study shows that while the combo drug decreases the chance of coronary artery disease, it doesn't work as well in slowing down aortic valve disease. So why is all the focus on cancer deaths?

After a year of layoffs and restructuring, Valeant Pharma scores big with a collaboration deal worth up to $670 million.

The Belgium-based drug maker is terminating 2,000 jobs and rebranding itself as a biopharm with a focus on CNS and immunology drugs. Pharm Exec gave UCB a call to find out more.

Designed to rein in the relationship between sales reps and doctors, PhRMA's new, revised code may end up having an adverse effect on clinical trials

Effective January 1st, sales reps will have a new standard for dealing with doctors the PhRMA way

FDA missteps and global outsourcing are drawing Congressional scrutiny and prompting new oversight approaches

Young & Partners crunches pharma's filings for, the first half of '08. The results? Ask the Japanese

The Orphan Drug Act was passed 25 years ago. But the challenge of actually getting rare disease drugs and therapies to patients still remains

A new study tracks six high-traffic drugs that are turning up on shady online pharmacies, usually at huge discounts. The conclusion: Fancy Web sites are suckering customers and costing pharma money and credibility.

The case for preemption gets shot down in Texas, but holds up in yet another Medtronic suit in Minnesota.

Margaret McGlynn, Merck's head of vaccines, expounded yesterday on the state of the company's vaccine program, including campaign strategies, product development, and a new reimbursement program for doctors.

Do consumers pay attention to risk information in television ads? FDA plans to find out with a study using phony ads for a nonexistent blood pressure drug.

Crohn?s disease is the topic of conversation on the first Abbott unbranded podcast. The company talks about why it went the radio route.

A new study reports that more than 27 percent of Americans are not being treated for HIV because they fear adverse reactions to the drugs. Pharm Exec talked to the doctors in charge of the survey to learn more.

There's a cure for everything, as long as the patient is a mouse

After years of owning a majority share in Genentech, Roche makes a play to buy out the rest of the biotech firm.

Pfizer, Schering, Abbott, and Boehringer announced that they will be shifting and slashing staff at both sales and manufacturing levels. While much smaller in scope than earlier cuts, the bloodletting doesn?t seem to be over.

The new Phrma marketing code bans pens and pads and other non-educational gifts. It bans dinners with docs (but not the lunch-and-learn). And it requires compliance. Are we safer yet?

The Johnson & Johnson subsidiary launched an unbranded support group page on social networking site Facebook giving moms of kids with ADHD a place to learn, but not a place to converse.

Johnson & Johnson launched its healthcare video channel on Google?s YouTube, signaling pharma?s further entrenchment into the online community

Fresenius snagged injectible manufacturer APP Pharmaceuticals in a $3.7 billion cash deal. Along with entry into the US market, Fresenius also gets access to one of the largest suppliers of heparin.

A new global CEO study examines what near- and long-term changes pharma leaders expect to face and in what areas they are planning to focus their attention. Key focus areas: global business design and new markets.

With the launch of the Center for Communication Compliance, pharma companies and PR firms have a one-stop resource to educate themselves about marketing regulations in an effort to reduce accidental non-compliance.

Rejection is tough to take, but leaders have the drive and ability to bounce back from a setback with boundless energy

It's not that I disagree with the Obama and McCain healthcare proposals. It's that there's nothing actually there to disagree with

Rare disease treatments are riding high as patient adcovates, pharma companies, and government officials celebrate the ODA's 25th anniversary

Genentech had previously been number one by a very wide margin. This year, that margin started to narrow. Novartis is now a much closer second

No, it's not as glamorous as its double-helixed offspring. But recent revelations about RNA turn even cold-eyed scientists into lyrical romantics